Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech, Inc. has amended the terms of its Remuneration Committee, initially established in 2019, to oversee executive compensation. The committee, exclusively composed of non-executive Directors, primarily independent ones, ensures fair and competitive remuneration practices within the company. Appointments to the committee are for up to three years, subject to extensions, maintaining a focus on independent oversight.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.
